A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Hyperammonaemia
- Focus Adverse reactions; Registrational
- Sponsors Hyperion Therapeutics
Most Recent Events
- 30 Nov 2015 According to Horizon Pharma media release, the European Commission has approved glycerol phenylbutyrate oral liquid (RAVICTI) for treatment of urea cycle disorders in patients two months of age and older.
- 26 Jun 2014 New trial record